Neuraly, Inc.
- Country
- πΊπΈUnited States
- Ownership
- Holding, Subsidiary
- Established
- 2016-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.neuralymed.com
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)β’ Click on a phase to view related trials
A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH
- First Posted Date
- 2024-05-13
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- Neuraly, Inc.
- Target Recruit Count
- 67
- Registration Number
- NCT06410924
- Locations
- πΊπΈ
Summit Research Site, San Antonio, Texas, United States
A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLD
- Conditions
- NAFLDOverweight and ObesityType2 Diabetes
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-03-23
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Neuraly, Inc.
- Target Recruit Count
- 255
- Registration Number
- NCT04812262
- Locations
- πΊπΈ
Prosciento, Chula Vista, California, United States
πΊπΈSouthwest General Healthcare Center, Fort Myers, Florida, United States
πΊπΈCombined Research Orlando, Orlando, Florida, United States
A Study With NLY01 in Subjects With Type 2 Diabetes
- Conditions
- Type2 DiabetesDiabetes Mellitus, Type 2
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-11-12
- Last Posted Date
- 2021-03-02
- Lead Sponsor
- Neuraly, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04159766
- Locations
- π©πͺ
Profil Institute fur Stoffwechselforschung GmbH, Neuss, Germany
π©πͺProfil Institute, Neuss, Germany
A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease
- First Posted Date
- 2019-11-06
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Neuraly, Inc.
- Target Recruit Count
- 255
- Registration Number
- NCT04154072
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈSt. Joseph's Hospital and Medical Center - Barrow Neurological Institute, Phoenix, Arizona, United States
πΊπΈMovement Disorders Center, Scottsdale, Arizona, United States
A Phase 1 Study to Assess the Safety of NLY01 in Healthy Subjects
- First Posted Date
- 2018-09-14
- Last Posted Date
- 2019-09-30
- Lead Sponsor
- Neuraly, Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT03672604
- Locations
- πΊπΈ
ICON Early Phase Services/CRU, San Antonio, Texas, United States